Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers

Cancer–testis antigen NY-ESO-1 is one of the most immunogenic tumor antigens defined to date. Spontaneous humoral and CD8+ T-cell responses to NY-ESO-1 are detected in 40–50% of patients with advanced NY-ESO-1-expressing tumors. A clinical trial was initiated to study the immunological effects of in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jäger, Elke, Gnjatic, Sacha, Nagata, Yasuhiro, Stockert, Elisabeth, Jäger, Dirk, Karbach, Julia, Neumann, Antje, Rieckenberg, Julia, Chen, Yao-Tseng, Ritter, Gerd, Hoffman, Eric, Arand, Michael, Old, Lloyd J., Knuth, Alexander
Format: Artigo
Idioma:Inglês
Publicat: The National Academy of Sciences 2000
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC17318/
https://ncbi.nlm.nih.gov/pubmed/11027314
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars